Dr Reddy's Labs gets USFDA EIR for IPDO facility
New Delhi: Dr. Reddy''s Laboratories on Thursday said the US health regulator has closed inspection of its Telangana-based facility.
The company has received the establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for Medchal-Malkajgiri-based integrated product development organization (IPDO) indicating closure of the audit, Dr. Reddy''s Laboratories said in a regulatory filing.
The USFDA issues an EIR to a company when an inspection is satisfactorily closed.
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, committed to providing affordable and innovative medicines for healthier lives.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
The Company's markets include – USA, India, Russia & CIS countries, and Europe.
Read also: Dr Reddy's Labs gets USFDA EIR for Hyderabad facility
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.